Publication | Closed Access

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

Hematological MalignancyLymphoid NeoplasiaSubcutaneous AlemtuzumabAutoimmune DiseaseCellular Immune ReconstitutionHematologyImmunologyImmune Checkpoint InhibitorAutoimmunityImmunotherapyMedicineRadiation OncologyAnti-cd52 Monoclonal AntibodyHealth Sciences